Neuren Pharmaceuticals Ltd (NEU) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.397x

Based on the latest financial reports, Neuren Pharmaceuticals Ltd (NEU) has a cash flow conversion efficiency ratio of 0.397x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$128.31 Million ≈ $90.78 Million USD) by net assets (AU$323.27 Million ≈ $228.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Neuren Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2002–2024)

This chart illustrates how Neuren Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Neuren Pharmaceuticals Ltd (NEU) total liabilities for a breakdown of total debt and financial obligations.

Neuren Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Neuren Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Wah Lee Industrial Corp
TW:3010
0.023x
Hubei Tech Semiconductors Co
SHE:300046
0.008x
Wavestone S.A.
PA:WAVE
0.032x
Fujian Longxi Bearing Group Co Ltd
SHG:600592
0.011x
Fujian Boss Software Development Co Ltd
SHE:300525
0.016x
Chengdu Zhimingda Electronics Co. Ltd. A
SHG:688636
-0.049x
Jiangxi Firstar Panel Technology Co Ltd
SHE:300256
0.107x
BIRLASOFT LIMITED
NSE:BSOFT
0.049x

Annual Cash Flow Conversion Efficiency for Neuren Pharmaceuticals Ltd (2002–2024)

The table below shows the annual cash flow conversion efficiency of Neuren Pharmaceuticals Ltd from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see Neuren Pharmaceuticals Ltd market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 AU$363.90 Million
≈ $257.49 Million
AU$-11.27 Million
≈ $-7.97 Million
-0.031x -103.44%
2023-12-31 AU$205.21 Million
≈ $145.20 Million
AU$184.93 Million
≈ $130.85 Million
0.901x +941.36%
2022-12-31 AU$41.59 Million
≈ $29.43 Million
AU$3.60 Million
≈ $2.55 Million
0.087x +134.07%
2021-12-31 AU$39.25 Million
≈ $27.77 Million
AU$-9.97 Million
≈ $-7.05 Million
-0.254x +23.91%
2020-12-31 AU$24.20 Million
≈ $17.12 Million
AU$-8.08 Million
≈ $-5.72 Million
-0.334x +60.56%
2019-12-31 AU$13.85 Million
≈ $9.80 Million
AU$-11.72 Million
≈ $-8.29 Million
-0.846x -425.81%
2018-12-31 AU$24.67 Million
≈ $17.45 Million
AU$6.41 Million
≈ $4.53 Million
0.260x +176.04%
2017-12-31 AU$16.36 Million
≈ $11.58 Million
AU$-5.59 Million
≈ $-3.96 Million
-0.342x +88.46%
2016-12-31 AU$4.18 Million
≈ $2.96 Million
AU$-12.38 Million
≈ $-8.76 Million
-2.959x -234.75%
2015-12-31 AU$14.40 Million
≈ $10.19 Million
AU$-12.73 Million
≈ $-9.01 Million
-0.884x -163.10%
2014-12-31 AU$19.08 Million
≈ $13.50 Million
AU$-6.41 Million
≈ $-4.54 Million
-0.336x -6.14%
2013-12-31 AU$24.36 Million
≈ $17.23 Million
AU$-7.71 Million
≈ $-5.45 Million
-0.317x +31.96%
2012-12-31 AU$6.34 Million
≈ $4.49 Million
AU$-2.95 Million
≈ $-2.09 Million
-0.465x -40.59%
2011-12-31 AU$9.45 Million
≈ $6.69 Million
AU$-3.13 Million
≈ $-2.21 Million
-0.331x +59.31%
2010-12-31 AU$3.53 Million
≈ $2.50 Million
AU$-2.87 Million
≈ $-2.03 Million
-0.813x -364.34%
2009-12-31 AU$7.35 Million
≈ $5.20 Million
AU$-1.29 Million
≈ $-910.66K
-0.175x +89.20%
2008-12-31 AU$5.57 Million
≈ $3.94 Million
AU$-9.04 Million
≈ $-6.40 Million
-1.622x -6.50%
2007-12-31 AU$7.55 Million
≈ $5.34 Million
AU$-11.50 Million
≈ $-8.14 Million
-1.523x -169.10%
2006-12-31 AU$16.15 Million
≈ $11.42 Million
AU$-9.14 Million
≈ $-6.47 Million
-0.566x -116.92%
2005-12-31 AU$32.16 Million
≈ $22.75 Million
AU$-8.39 Million
≈ $-5.94 Million
-0.261x +37.81%
2004-12-31 AU$8.77 Million
≈ $6.20 Million
AU$-3.68 Million
≈ $-2.60 Million
-0.420x -232.00%
2003-12-31 AU$-14.72 Million
≈ $-10.41 Million
AU$-4.68 Million
≈ $-3.31 Million
0.318x +111.17%
2002-12-31 AU$1.82 Million
≈ $1.29 Million
AU$-5.19 Million
≈ $-3.67 Million
-2.846x --

About Neuren Pharmaceuticals Ltd

AU:NEU Australia Biotechnology
Market Cap
$1.12 Billion
AU$1.58 Billion AUD
Market Cap Rank
#8654 Global
#210 in Australia
Share Price
AU$12.45
Change (1 day)
-1.19%
52-Week Range
AU$11.28 - AU$21.98
All Time High
AU$25.11
About

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 cl… Read more